Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer DOI Creative Commons
Xin-wen Wang, Min Wang,

Qijun Lin

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 12(2)

Published: Nov. 20, 2024

Abstract Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts microenvironment secrete increased levels extracellular matrix protein 1 (ECM1), which affects surrounding cancer cells, promoting tumor cell proliferation and anti‐androgen resistance. Mechanistically, ECM1 interacts with enolase (ENO1) receptor on membrane, leading its phosphorylation at Y189 site. This event further recruits adapter proteins including growth factor receptor‐bound 2 (GRB2) son sevenless homolog (SOS1), activates downstream mitogen‐activated kinase (MAPK) signaling pathway induce Furthermore, inhibiting or utilizing ENO1‐targeting inhibitor phosphonoacetohydroxamate (PhAH) significantly restores sensitivity ENZ. Taken together, potential mechanism identified through osteoblast‐derived drives treatment. Additionally, findings indicate ENO1 may serve as targets for developing therapies castration‐resistant

Language: Английский

From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections DOI Creative Commons
André Sarmento‐Cabral, Antonio C. Fuentes-Fayos, Fernando Mata Ordóñez

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 6, 2025

Abstract The prostate gland is an endocrine-sensitive organ responding to multiple stimuli. Its development and function are regulated by hormones (i.e. steroids such as androgens, estrogens glucocorticoids) but also other key hormonal systems those comprised insulin-like growth factor 1 insulin, which sourced different tissues [e.g. testicles/adrenal-gland/adipose-tissue/liver/pancreas, etc.). Particularly important for the endocrine control of prostatic pathophysiology anatomy produced and/or secreted cell types pituitary [growth-hormone, luteinizing-hormone, follicle-stimulating hormone, prolactin, oxytocin, arginine-vasopressin melanocyte-stimulating hormone], affect either directly or indirectly under physiological pathophysiological conditions metabolic dysregulation (e.g. obesity), transformations cancer)]. This review summarizes impact all hormone on these diverse including in vivo vitro studies.

Language: Английский

Citations

0
ARRB2 as a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma: Insights from integrated RNA and single-cell sequencing DOI Creative Commons
Wenjun Meng,

Yihang Luo,

Tao Qin

et al.

Asian Journal of Surgery, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Prolactin as a novel biomarker in malignancy DOI

Sahel Safdari,

Sahel Safdari,

Parisa Noorabadi

et al.

Clinica Chimica Acta, Journal Year: 2025, Volume and Issue: unknown, P. 120277 - 120277

Published: March 1, 2025

Language: Английский

Citations

0
B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer DOI Creative Commons
Wei Yao, Yihui Wang, Xin Zhang

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(10), P. 110889 - 110889

Published: Sept. 6, 2024

Language: Английский

Citations

1
Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer DOI Creative Commons
Xin-wen Wang, Min Wang,

Qijun Lin

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 12(2)

Published: Nov. 20, 2024

Abstract Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts microenvironment secrete increased levels extracellular matrix protein 1 (ECM1), which affects surrounding cancer cells, promoting tumor cell proliferation and anti‐androgen resistance. Mechanistically, ECM1 interacts with enolase (ENO1) receptor on membrane, leading its phosphorylation at Y189 site. This event further recruits adapter proteins including growth factor receptor‐bound 2 (GRB2) son sevenless homolog (SOS1), activates downstream mitogen‐activated kinase (MAPK) signaling pathway induce Furthermore, inhibiting or utilizing ENO1‐targeting inhibitor phosphonoacetohydroxamate (PhAH) significantly restores sensitivity ENZ. Taken together, potential mechanism identified through osteoblast‐derived drives treatment. Additionally, findings indicate ENO1 may serve as targets for developing therapies castration‐resistant

Language: Английский

Citations

1